Bactiguard’s urinary catheters approved for reimbursement in the Dutch market

Bactiguard’s indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life.

To be able to sell medical devices to the Dutch home care providers in a broader scale, the products must be reimbursed. Bactiguard’s Foleys are now included, which means that our partner in the Netherlands, Mediplast, can start to offer the products to a larger group of patients.

“The homecare market offers the biggest market potential for Foley catheters in the Netherlands. Now that our products are reimbursed, we will increase the pace of expansion in the country”, says Jonas Östregård, SVP Sales & Marketing at Bactiguard.

“I am so pleased to be able to offer Bactiguard’s infection preventive products to Dutch home care patients and thereby reduce the risk of hospital acquired infections and improve their quality of life. Now that the products are reimbursed, we can approach the homecare companies with a cost-effective solution for long term catheterized patients, which wasn’t possible before,” says Wil Graus, Sales and Managing Director at Mediplast Benelux.

Bactiguard and Mediplast have been partners since October 2018. The original agreement covered sales and distribution of Bactiguard’s product portfolio for infection prevention (BIP) in Scandinavia. Already in December the same year, the partnership was extended to include Belgium, the Netherlands and Luxembourg.

Bactiguard’s infection protection (BIP) solutions, which include products for the urinary tract, blood stream and respiratory tract, reduce the risk of healthcare associated infections, the use of antibiotics and thus the spread of multi-resistant bacteria. 


For further information, please contact:
Jonas Östregård, SVP Sales & Marketing cell phone: +46 70 521 13 88

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com

Tags:

About Us

Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of foley catheters, central venous catheters and endotrachealtubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 70 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com